# OpACIN-neo (NCT02977052)

> Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02977052
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: The Netherlands Cancer Institute
- Conditions: Malignant Melanoma Stage III
- Interventions: Ipilimumab; Nivolumab; Surgery; Blood for PBMCs; Biopsies
- Enrollment: 186
- Primary outcome: Safety as measured by the frequency of grade 3/4 immune-related adverse events, using CTCAE 4.03
- Primary outcome: Response rate according to RECIST 1.1
- Primary outcome: Pathological response according to central pathological revision, according to pathological response criteria
- Primary outcome: Pathologic response rate according to central revision of the marked index lymph node
- Primary outcome: RFS at 24 months in patients achieving pCR or pnCR in their marked index lymph node and did not undergo CLND. RFS will be calculated from date of resection of the marked lymph node.
- Primary outcome: RFS at 24 months in patients with pNR and being subsequently treated with adjuvant nivolumab+optional radiotherapy (or dabrafenib/trametinib if BRAFV600E pos. and treatment is approved). RFS will be calculated from day of resection of marked lymph node.

## Commentary we found

- Podcasts: 12
- YouTube: 6
- X threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=opacin-neo-nct02977052

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02977052", "email": "<work email>"}; the inbox owner confirms by the emailed link.